

1 Evaluation of a new spike (S) protein based commercial immunoassay for the detection 2 of anti-SARS-CoV-2 IgG

3 Kirsten Alexandra Eberhardt^{1,2*}, Felix Dewald^{3,4*}, Eva Heger³, Lutz Gieselmann³, Kanika
4 Vanshylla^{3,4}, Maike Wirtz³, Franziska Kleipass³, Wibke Johannis⁵, Philipp Schommers^{3,6,7},
5 Henning Gruell^{3,7}, Karl August Brensing⁸, Roman-Ulrich Müller^{4,9,10}, Max Augustin⁶, Clara
6 Lehmann^{4,6,7}, Manuel Koch^{4,11}, Florian Klein^{3,4,7} and Veronica Di Cristanziano^{3,4#}

7 ¹ Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Dep. of Medicine
8 University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany

9 ² Institute for Transfusion Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany

10 ³ Institute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50935
11 Cologne, Germany

12 ⁴ Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany

13 ⁵ Institute for Clinical Chemistry, Faculty of Medicine and University Hospital of Cologne, University of
14 Cologne, 50937 Cologne, Germany

15 ⁶ Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of
16 Cologne, 50937 Cologne, Germany

17 ⁷ German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 50931 Cologne, Germany

18 ⁸ Nierenzentrum Bonn, Godesberger Allee 26, 53175 Bonn, Germany

19 ⁹ Department II of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of
20 Cologne, 50937 Cologne, Germany

21 ¹⁰ Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, CECAD, University
22 of Cologne, 50931 Cologne, Germany

23 ¹¹ Institute for Experimental Dentistry and Oral Musculoskeletal Biology, and Center for Biochemistry, Faculty
24 of Medicine and University Hospital of Cologne, University of Cologne, 50931 Cologne, Germany

25

26 * These authors contributed equally to this work

27 # Correspondence: veronica.di-cristanziano@uk-koeln.de; Tel:+49-221-478-85828

28

29 Abstract

30 **Background:** The investigation of antibody response to SARS-CoV-2 represents a key aspect
31 in facing the COVID-19 pandemic. In the present study, we compared one new and four
32 widely used commercial serological assays for the detection of antibodies targeting S (spike)
33 and NC (nucleocapsid) protein. **Methods:** Serum samples from a group of apparently non-
34 responders, from an unbiased group of convalescent patients and from a negative control
35 group were simultaneously analyzed by the LIAISON® SARS-CoV-2 S1/S2 IgG test,
36 Euroimmun anti-SARS-CoV-2 S1 IgG ELISA and IDK® anti-SARS-CoV-2 S1 IgG assays.
37 IgG binding NC were detected by the Abbott SARS-CoV-2 IgG assay and by the pan-
38 immunoglobulin immunoassay Elecsys® Anti-SARS-CoV-2. Additionally, samples were also
39 tested by live virus and pseudovirus neutralization tests. **Results:** Overall, about 50% of
40 convalescent patients with undetectable IgG antibodies using the commercial kit by
41 Euroimmun were identified as IgG positive by Immundiagnostik and Roche. While both
42 assays achieved similarly high sensitivities, Immundiagnostik correlated better with serum
43 neutralizing activity than Roche. **Conclusions:** Although the proportion of IgG seropositive
44 individuals appears to be higher using more sensitive immunoassays, the protective ability
45 and the potential to serve as indirect markers of other beneficial immune responses warrants
46 for further research.

47

48 **Keywords:** pandemic; humoral response; neutralization; titer; protection; non-responder;
49 coro-navirus; antibody; COVID-19; sensitivity

50

51

52 **Introduction**

53 The investigation of humoral response to SARS-CoV-2 represents a key aspect in facing the
54 COVID-19 pandemic. Although neutralizing antibodies are considered to have an important
55 protective role, the association between seropositivity and immunity, as well as the duration
56 of protective humoral response represent key questions of current research [1-4]. The FDA
57 declared a neutralizing titer $\geq 1:160$ as sufficient for plasma donations. However, the
58 definition of an antibody titer conferring protection is still missing [5].

59 Virus-neutralizing (VN) assays, based on live virus or pseudovirus, are considered the gold
60 standard to conclude on the presence and quantity of specific neutralizing antibodies.
61 However, they are time intensive and require biosafety level 2 or 3 facilities [6]. Most routine
62 diagnostic facilities instead make use of commercially serological immunoassays and high-
63 throughput automated platforms [7]. Various methods for antibody detection are available,
64 including chemiluminescence immunoassay (CLIA), chemiluminescent microparticle
65 immunoassay (CMIA), electrochemiluminescence immunoassay (ECLIA) and enzyme-linked
66 immunosorbent assay (ELISA). They can be divided into assays that recognize specific anti-
67 SARS-CoV-2 antibodies against the spike (S) protein (Figure 1A) with the receptor-binding
68 domain (RBD) and on the other hand in those detecting antibodies targeting the nucleocapsid
69 (NC) protein [8]. Neutralizing antibodies mainly target the RBD domain [6, 9]. Hence, S-
70 protein based assays could be considered more suitable as surrogate for protection [10].

71 The number of studies providing data about the performance of various serological assays
72 massively increased. So far, the Roche Elecsys, a pan-IG assay for the detection of anti-NC
73 antibodies, was reported to be one of the most sensitive SARS-CoV-2 antibody detection
74 assays [11]. However, it correlated less with neutralizing titers as compared to assays
75 detecting anti-S antibodies [10]. Consequently, despite the ability of the Roche assay to
76 diagnose previous SARS-CoV-2 infection, the potential to predict protection against
77 reinfection is questionable.

78 A continuous evaluation of commercial assays targeting the S protein has a growing relevance
79 for many reasons. The intensity of antibody response can largely vary in asymptomatic and
80 mild COVID-19 cases, and a relevant proportion of these patients apparently fail to generate a
81 detectable humoral response to SARS-CoV-2 [12-14]. In addition, there are contradictory
82 observations on the persistence of specific antibody levels over time in these groups [15-19].
83 In case of anti-NC antibodies, a drop in sensitivity over time was already reported for some
84 serological assays [10]. For this reason, it is of outstanding importance to investigate if non-

85 detection is equal to absence or just a result of imprecise laboratory assessment methods.
86 Firstly, because seroprevalence could be underestimated [20, 21]. Secondly, considering the
87 results indicating a generation of a stable and potent B memory response, a booster effect
88 regardless of detectable serum antibody levels cannot be excluded as mechanism of protection
89 from infection and/or disease [22, 23]. So far, despite apparently high rates of low- or non-
90 responders, reinfections with SARS-CoV-2 are still reported to be a rare event [24]. Based on
91 these considerations, assay sensitivity could represent a decisive aspect to understand the
92 mechanisms underlying protective humoral responses. Furthermore, highly sensitive S-based
93 protein assays could be relevant for defining time intervals for vaccine boosters, as well as for
94 long term antibody response studies upon vaccination. Finally, the possibility to combine S-
95 and NC-based proteins assays with similar high sensitivity and specificity will be increasingly
96 required to answer the important question of SARS-CoV-2 infection despite active
97 immunization.

98 Here, we evaluate sensitivity and specificity of a novel S-protein based commercial assay for
99 the detection of serum anti-SARS-CoV-2 IgG. Analyzed samples have been obtained from a
100 cohort of convalescent individuals, mostly recovered from mild COVID-19, recruited at a
101 German University Hospital since April 2020 [16]. In particular, we focused on so-called
102 “non-responders”, here defined as individuals with undetectable serum IgG antibodies as
103 tested with the immunoassay by Euroimmun in our routine laboratory. Additionally, the
104 performance of the new assay by Immundiagnostik was compared to three other IgG
105 qualitative immunoassays, including Roche Elecsys, Abbot (anti-NC IgG), and Diasorin (anti-
106 S1/S2 IgG). Moreover, the correlation between IgG levels and serum neutralizing activity was
107 investigated by live virus and pseudovirus neutralization assays.

108

109 **Materials and Methods**

110 *Ethical considerations*

111 All subjects gave their informed consent for inclusion before they participated in the study.
112 The study was conducted in accordance with the Declaration of Helsinki and samples were
113 collected and analyzed under protocols approved by the Institutional Review Board of the
114 University of Cologne, Germany (16-054 and 20-1187).

115 *Study population*

116 Serum samples were obtained from individuals with molecularly confirmed prior SARS-CoV-
117 2 infection recruited at a German University Hospital between April and September 2020.
118 Most patients recovered from mild COVID-19 and they did not require hospitalization.
119 Two subgroups were investigated: group A included all convalescent patients with previous
120 SARS-CoV-2 infection who attended the clinic between August and September 2020,
121 regardless of their IgG ratio values. Group B was considered as the group of individuals who
122 attended the clinic between April and July 2020 and were tested IgG negative or borderline in
123 our routine screening using the Euroimmun ELISA despite prior SARS-CoV-2 infection. As a
124 last group C, we considered samples collected in 2020 from individuals without any suspicion
125 for SARS-CoV-2 infection, as well as serum samples obtained in 2019 as a negative control
126 group.

127

128 *Serological testing for the detection of anti-SARS-CoV-2 antibodies*

129 *Commercial assays*


130 Serum samples from groups A, B and C were simultaneously analyzed by five different
131 commercial assays for the detection of anti-SARS-CoV-2 antibodies (Supplementary Table
132 1).

133 Anti-SARS-CoV-2 IgG targeting the S protein (CLIA) were detected by the LIAISON®
134 SARS-CoV-2 S1/S2 IgG test on the LIAISON® XL (DiaSorin, Vicenza, Italia), by the
135 Euroimmun anti-SARS-CoV-2 IgG ELISA on the Euroimmun Analyzer I (Euroimmun
136 Diagnostik, Lübeck, Germany), and by the IDK® anti-SARS-CoV-2 IgG ELISA
137 (Immundiagnostik AG, Bensheim, Germany) on the DYNEX DSX® (Dyner Technologies,
138 Chantilly, USA). The two latter ELISA assays use the recombinant S1 antigen from of the
139 spike protein (Figure 1).

140 NC protein antibodies were detected by the SARS-CoV-2 IgG assay (CMIA) provided by
141 Abbott on the Alinity I (Abbott, Abbott Park, Illinois, United States) and by the pan-
142 immunoglobulin immunoassay Elecsys® Anti-SARS-CoV-2 (ECLIA) on the Cobas e (Roche
143 Diagnostics, Mannheim, Germany).

144 All assays were interpreted according to manufacturer's recommendations. IgG values by
145 Immundiagnostik were capped at 3.8 OD at the upper end for analysis. In case of the assays
146 by Euroimmun and DiaSorin, borderline results were counted as negative. However, we
147 alternatively recalculated our findings counting borderline results as positive to evaluate if test
148 performances would profoundly differ.

149



150

151 **Figure 1. A)** Schematic drawing of the SARS-CoV-2 virus. Spike (S) and nucleocapsid (N)
152 proteins are highlighted. **B)** Schematic drawing of the trimeric S protein. **C)** The domain
153 structure of the S protein is shown and the three regions which were tested are depicted. All
154 three versions contain the receptor binding domain (RBD). **D)** The ELISA procedure is
155 outlined. SP, signal peptide, NTD, N-terminal domain, S1, spike protein subunit 1, S2, spike
156 protein subunit 2, FP, fusion peptide, HR1, heptad repeat 1 domain, HR2, heptad repeat 2
157 domain, TM, transmembrane domain, FD, foldon motif

158

159 *Live virus assay to determine SARS-CoV-2 neutralizing activity (LVN)*

160 After inactivation of complement by heating at 56° for 30 minutes, serum samples were
161 diluted 1:10 and 1:50 in 2-folds in DMEM medium (Dulbecco Dulbecco's Modified Eagle's
162 Medium, Gibco, Dublin, Ireland) and mixed with 100 TCID₅₀ (Tissue culture infectious dose
163 50) of wild type virus (isolated from a patient at the University Hospital of Cologne) to a
164 volume of 100 µL. Virus-serum mixture was incubated for one hour at 37°C. Afterwards, 50
165 µl of VERO E6 cell suspension (250.000 cells/ml) were added to each sample dilution. Cell
166 plates were incubated at 37° for 4 days before to microscopically determine the virus-related
167 cytopathic effects (CPE).

168 *Pseudovirus assay to determine SARS-CoV-2 neutralizing activity (PVN)*

169 For testing SARS-CoV-2 neutralizing activity using pseudovirus, serial dilutions of serum
170 (heat inactivated at 56°C for 45 min) were coincubated with pseudovirus supernatants for 1 h
171 at 37°C and thereafter, 293T cells engineered to express ACE2 were added [25]. After a 48-
172 hour incubation at 37°C and 5% CO₂, luciferase activity was determined after addition of
173 luciferin/lysis buffer (10 mM MgCl₂, 0.3 mM ATP, 0.5 mM Coenzyme A, 17 mM IGE-PAL
174 (all Sigma-Aldrich), and 1 mM D-Luciferin (GoldBio) in Tris-HCL) using a micro-plate
175 reader (Berthold). After subtracting background relative luminescence units (RLUs) of un-
176 infected cells, 50% Inhibitory dose (ID₅₀) was determined as the serum dilution with 50%
177 RLU reduction compared to untreated virus control wells. Every serum sample was measured
178 on different days in two independent experiments and the mean ID₅₀ values is presented.

179 *Statistical Analysis*

180 Continuous variables were expressed as median (interquartile range, IQR) or mean ± standard
181 deviation (SD) and compared using the Wilcoxon rank sum test or the unpaired Student's t-
182 test. Categorical variables were compared using either the χ^2 test or the Fisher exact test, as
183 appropriate. The Spearman rank correlation coefficient ρ was calculated as measure of
184 strength of the relationship between serological assay outcomes and the pseudovirus
185 neutralization assay. The correlation between the 3-level ordinal live virus neutralization
186 assay outcome and categorized binary outcomes of serologic assays, was evaluated by
187 calculating the Kendall's coefficient of rank correlation τ . Additionally, two neutralizing
188 cutoff titers were assessed for their concordance with the binary outcomes of the commercial
189 serological assays using the Cohen's κ . Two-sided p-values were presented, and an α of 0.05
190 was determined as the cutoff for significance. All statistical analyses were performed using R
191 (version 3.6.3, R Foundation for Statistical Computing, Vienna, Austria).

192 **Results**

193 *Establishment of a new SARS-CoV-2 serological test*


194 Serological tests mainly focus on the S and NC protein from the SARS-CoV-2 virus (Figure
195 1A, 1B). As the S protein might be the most crucial protein for the infection, different regions
196 of the S protein have been compared and evaluated for the use in an ELISA kit. Three
197 different regions, S protein ectodomain, RBD, and S1 truncated, have been recombinantly
198 expressed in HEK293 cells and intensively tested (Figure 1C). The S1 truncated was chosen
199 for further usage since it performed best in different tests. According to Immundiagnostik, 7
200 out of 762 plasma samples, collected between 2017 and 2018, tested positive for the SARS-
201 CoV-2 by ELISA. Furthermore, no cross reactivity to plasma probes for Adenovirus, Epstein-

202 Barr-Virus, Influenza A/B, HCoV-229E, HCoV-HKU1, HCoV-NL63, and HCoV-OC43 was
203 detected. Additional information can be obtained from in the Immundiagnostik manual.

204 *Sensitivity of five commercially available serological tests and two virus-neutralizing immu-*
205 *noassays in a cohort with previous infection with SARS-CoV-2 (group A)*

206 To evaluate the general sensitivity of serological tests with different antigen targets, we
207 compared three commercially available immunoassays targeting the S protein, two assays
208 detecting the NC protein, the combination of assays targeting different antigens, and two VN
209 assays (Supplementary Table 2). Serum samples of 363 convalescent patients with prior
210 SARS-CoV-2 infection collected between August and September 2020 (group A) were used
211 for this evaluation (Figure 2A). In this group 5.9% of the individuals declared themselves as
212 asymptomatic, 89.8% participants had a mild course of disease, while 4.33% of the subjects
213 were hospitalized because of COVID-19. The median time between infection and antibody
214 determination was 154 days (Table 1). As indicated by Figure 2B, the sensitivities achieved
215 by immunoassays targeting the S protein ranged between 77.1% and 89.2% with the assay by
216 Immundiagnostik being the most sensitive in that group. The serological tests detecting the
217 NC antigen performed vastly different. While the test by Roche achieved the highest
218 sensitivity (93.1%) of all assays, the Abbott immunoassay only reached 53.7% sensitivity in
219 this general cohort of recovered individuals. A combination of the best performing
220 immunoassays with different protein targets resulted in a sensitivity of 93.9%. Interestingly,
221 the sensitivity of 91% achieved by the VN assay was below the sensitivity of the
222 commercially available Roche test but higher than all the S protein targeting tests. 342
223 (94.2%) participants with past SARS-CoV-2 infection were tested IgG positive in at least one
224 of the immunoassays evaluated.

225



226

227

228

229 **Figure 2. A)** IgG ratio values of five commercially available immunoassays targeting the *S*

230 (*spike*) (blue) or the *NC* (nucleocapsid) protein (yellow) and virus-neutralizing assays (grey)

231 displayed against the weeks after infection for each individual from group A. Dashed

232 horizontal lines display cutoff values of individual serological assays. Results of the virus-

233 neutralizing immunoassay are categorized into <1:10, 1:10, and >=1:50. **B)** The sensitivity

234 in % achieved by assays against the *S* protein (blue), the *NC* antigen (yellow), the

235 combination of assays targeting the different proteins (red), and the VN test (grey) for group

236 A. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay

237

238 **Table 1.** Demographical and clinical characteristics of participants.

Parameters	Group A , n=363	Group B , n=169
Female, n (%)	200 (55.24)	103 (61.68)
Male, n (%)*	162 (44.75)	64 (38.32)
Age in years, mean \pm SD	44.09 \pm 12.86	42.69 \pm 12.86
Days after disease onset, median (IQR)	154 (141-176)	47 (35-56)
Asymptomatic, n (%)	15 (5.90)	20 (16.00)
Mild, n (%)	228 (89.77)	100 (80.00)
Severe, n (%)**	11 (4.33)	5 (4.00)

239 *SD, standard deviation; IQR, interquartile range; * no data available for 1 subject in group A and 2 subjects in*
240 *group B; ** no data available for 109 subjects in group A and 44 subjects in group B*

241

242 Figure 3A displays the correlation between the different commercial immunoassays and the
243 pseudovirus neutralization assay. The relationship between assays targeting the S domain is
244 strong with a Spearman rank correlation coefficient ρ ranging between 0.80 and 0.85. In
245 contrast to this, the relationship between the assays targeting the NC protein is slightly less
246 strong with $\rho=0.58-0.65$. The relation between live virus neutralization assay results and
247 those from the different commercial immunoassays are shown in Figure 3 B. The Kendall's τ
248 between the LVN assay and the serological assay ranges between 0.40 and 0.65 with higher
249 values for the assays targeting S protein antigens. Cohen's κ as a measure of concordance
250 between neutralizing titer cutoffs and binary results of serological assays ranged widely and
251 reached the highest value of 0.71 in case of the Immundiagnostik assay at a LVN-cut-off titer
252 of 1:10 and of the Euroimmun assay at a LVN cut-off of 1:50 ($\kappa=0.61$).

253

254

255

256


257

258

259

260

261



262

263

264 **Figure 3. A)** Correlation between five commercial anti-SARS-CoV-2 serological assays and
 265 pseudo-virus-neutralizing antibody titer for group A. R represents the Spearman rank
 266 correlation coefficient ρ . **B)** Correlation between five commercial anti-SARS-CoV-2
 267 serological assays and live virus neutralizing antibody titer for group A. Horizontal lines
 268 represent cutoff values for individual LVN commercial tests. Kendall's τ and Cohen's κ are
 269 displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus
 270 neutralization assay

271

272

273



274

275 *Sensitivity of four commercially available serological tests and two virus-neutralizing immunoassays in a cohort of non-responders (group B)*
 276

277 Between April and July 2020, 169 individuals with prior SARS-CoV-2 infection attending
 278 our clinic were classified as non-responders in the routine IgG screening using the
 279 Euroimmun ELISA (group B). In this group 16.0% of the subject were asymptomatic, 80.0%
 280 participants had a mild course of disease, and 4.0% of the subjects were hospitalized because
 281 of COVID-19. The median time interval between infection and antibody determination was
 282 47 days (Table 1).

283 By retesting the samples with two other assays against the S protein, two commercially
 284 available immunoassays targeting the NC protein, different test combinations, and two VN
 285 assays, we investigated which serologic test would perform best in detecting IgG seropositive
 286 individuals in this apparently non-responder population (Figure 4A and Supplementary Table
 287 3).

288




289

290 **Figure 4. A)** IgG ratio values of five commercially available immunoassays targeting the S
291 (spike) (blue) or the NC (nucleocapsid) protein (yellow) and virus-neutralizing assays (grey)
292 displayed against the weeks after infection for each individual from group B. Dashed
293 horizontal lines display cutoff values of individual serological assays. Results of the virus-
294 neutralizing immunoassay are categorized into <1:10, 1:10, and ≥1:50. **B)** The sensitivity
295 in % achieved by assays against the S protein (blue), the NC antigen (yellow), the
296 combination of assays targeting the different proteins (red), and the VN test (grey) for group
297 B. LVN, live virus neutralization assay; PVN, pseudovirus neutralization assay
298

299 While the DiaSorin immunoassay only detected very few patients as IgG positive (4.4%), the
300 test by Immundiagnostik found almost the half (49.06%) of this non-responder cohort to be
301 IgG positive. Exactly the same number of apparently non-responders (49.06%) were found to
302 be IgG positive using the Roche test. Remarkably, when combining the most sensitive tests
303 with different target proteins (Immundiagnostik and Roche), 94 out of 159 patients (59.1%)
304 were detected as seroconverted instead of being IgG negative as assumed after routine
305 screening with the Euroimmun assay (Figure 4B). Using two different virus-neutralizing
306 immunoassays, 38.8% and 35.3% of initially IgG negative participants were tested positive
307 for the presence of neutralizing antibodies. 97 (61%) individuals with past SARS-CoV-2
308 infection but undetectable IgG antibodies by the Euroimmun ELISA were classified as
309 seropositive in at least one of the other assays evaluated.

310 The correlation between the different commercial immunoassays and the pseudovirus
311 neutralization assay for the special sub-cohort of apparently non-responders is displayed in
312 Figure 5A. The relationships between the PVN assay and all evaluated commercial assays is
313 moderate with a Spearman rank correlation coefficient ρ ranging between 0.53 in case of the
314 Roche assay and 0.66 for the assay by Immundiagnostik. The relation between neutralization
315 assay using live virus results and those from the different commercial immunoassays in the
316 cohort of Euroimmun non-responders are shown in Figure 5B. The Kendall's τ between the
317 ordinal VN assay and the categorized serological tests ranges largely between 0.12 and 0.66
318 with the highest correlation observed with the Immundiagnostik assay. The correlation
319 coefficients between the LVN assay and the serological assays targeting the NC protein do
320 not differ profoundly from those measured in the unbiased convalescent cohort. The highest
321 concordance as determined by the Cohen's κ was observed at an LVN-titer of 1:10 with the
322 serologic assay of Immundiagnostik ($\kappa=0.67$), whereas it was negative ($\kappa=-0.05$) in case of
323 the DiaSorin assay at a neutralizing antibody cutoff-titer of 1:50 (Figure 5B).

324



325


326

327 **Figure 5. A)** Correlation between five commercial anti-SARS-CoV-2 serological assays and
 328 pseudo-virus-neutralizing antibody titer for group B. R represents the Spearman rank
 329 correlation coefficient ρ . **B)** Correlation between five commercial anti-SARS-CoV-2
 330 serological assays and live virus neutralizing antibody titer for group B. Horizontal lines
 331 represent cutoff values for individual commercial tests. Kendall's τ and Cohen's κ are
 332 displayed for each test combination. LVN, live virus neutralization assay; PVN, pseudovirus
 333 neutralization assay

334 *Specificity of five commercially available serological tests and one virus-neutralizing immu-*
335 *noassay in a SARS-CoV-2 negative control group (group C)*

336 We compared the performance in terms of specificity of five serological tests with different
337 antigen targets and one virus-neutralizing assay using a control group (group C, n=227) with
338 177 serum samples of individuals without suspected SARS-CoV-2 infection collected in 2020
339 and 50 serum samples that were collected in 2019 in our clinic. All assays or combination of
340 those achieved a specificity of 99-100% (Figure 6 and Supplementary Table 4).

341



342

343

344 **Figure 6.** The specificity achieved by assays against the S (spike) protein (blue), the NC
345 (nucleocapsid) antigen (yellow), and the combination of assays targeting the different
346 proteins (red) for group C.

347

348 Discussion

349 The detection of specific antibodies against defined infectious pathogens is commonly used as
350 marker of infection or protection. The determination of the serological immune status against
351 hepatitis B virus or measles are widely known examples of tests to evaluate individual
352 protection against these agents [26]. However, in case of SARS-CoV-2, it was observed that
353 profound proportions of patients can remain seronegative even months after infection or that
354 antibody levels wane over time, particularly in asymptomatic or mild courses of disease [27-
355 31]. Considering that the majority of COVID-19 cases have a mild symptomatic course of
356 disease, it is of outstanding importance to well characterize individuals with low or
357 undetectable serum IgG response and investigate, if non-detection is equal to absence or just a
358 result of imprecise laboratory assessment methods [12].

359 In the present study, we evaluated the performance of a novel ELISA commercial assay
360 approved for the detection of anti-SARS-CoV-2 IgG targeting epitopes within the S1 region
361 in patients recovered from mostly mild COVID-19. In particular, we studied two different
362 sub-cohorts of convalescent individuals, one unbiased group of recovered patients and one
363 group of apparently serological non-responders that were tested IgG seronegative by
364 Euroimmun.

365 To our knowledge, this is the first study investigating the performance of common serological
366 commercial assays in a target non-responder group recovered from mild COVID-19.

367 The evaluation of serologic immunoassays in the general cohort of individuals with previous
368 SARS-CoV-2 infection unraveled varying test performances. In line with other works, tests
369 targeting the S protein ranged between a sensitivity of 77.1% in case of the Euroimmun IgG
370 ELISA [32], and 89.2% achieved by the new serologic test by Immundiagnostik. Differently
371 from previous data, the Abbott Alinity IgG assay achieved a profoundly lower sensitivity
372 compared to the Roche immunoassay (53.7% and 93.1%, respectively) [33].

373 In the sub-cohort of apparently non-responders, defined as individuals with undetectable IgG
374 antibodies by the Euroimmun IgG ELISA despite confirmed prior SARS-CoV-2 infection, we
375 detected a remarkably high proportion of patients that produced specific anti-SARS-CoV-2
376 IgG antibodies. Whereas the assay by DiaSorin detected IgG in only 4% of these patients, the
377 Abbot assay was able to detect antibodies in 33% of the same individuals. The tests by
378 Immundiagnostik and Roche, both found 49.1% of the apparently non-responders to produce
379 IgG serum antibodies against SARS-CoV-2. When combining these two immunoassays with
380 the highest detection rate, this proportion reached even 59.1%. This noticeable result confirms
381 that almost 60% of the participants tested seronegative by Euroimmun are instead IgG
382 seropositive.

383 The moderate performance of the Allinity Abbot assay in our study is in line with the results
384 by Muecksch et al. [10]. The authors reported a decay of the sensitivity from >90% within the
385 first 40 days post-infection to 71% in samples tested more than 80 days after diagnosis when
386 tested with the Abbott immunoassay, whereas Roche Elecsys titers stayed stable overtime.
387 Similarly, in the present study, the Abbot assay was shown to be much less sensitive in
388 comparison to all other commercial assays in the unbiased cohort of convalescent patients
389 (group A) who were tested after a median time of 154 days post-infection. In contrast to this,
390 the difference between the Abbott and the Roche assays was less prominent in the group of
391 apparently “non-responders” (group B). This group was tested for the presence of antibodies
392 already after a median time of 47 days after SARS-CoV-2 infection. Muecksch et al.

393 suggested that the different performance of the two NC assays may be attributable to the
394 antigen bridging approach characterizing the Roche assay, which measures the evolution of
395 antibody binding properties despite their decay in total amount over time. Therefore, it is
396 advisable to prefer the technology by Roche for the detection of NC IgG antibodies.

397 Overall, these data confirmed previous conclusions that disease severity and time since
398 infection can critically impact on the declared sensitivity of commercial SARS-CoV-2 se-
399 rological assays. Furthermore, the S protein appears to be a more reliable target than the NC
400 region [20, 34].

401 Our data suggest that the performance of the Immundiagnostik assay in terms of sensitivity is
402 similarly high compared to the assay by Roche in both subgroups. This indicates that lower
403 antibody concentrations do not imply a loss of sensitivity despite the high specificity of both
404 assays. However, the Immundiagnostik assays might be preferred over the one by Roche for
405 the practical reasons that it can be used manually or by different automated platforms without
406 the issue of a short onboard stability as it is the case for the Roche kit.

407 Among the S-protein based assays, Immundiagnostik achieved the highest sensitivity. A
408 potential explanation for the superiority of the new serologic test by Immundiagnostik
409 compared to the widely used IgG Euroimmun, both targeting S1, could be that different parts
410 of the S-protein from SARS CoV-2 were used. For the development of the Immundiagnostik
411 ELISA kit, three different regions of the S-protein were tested. The most robust signal with
412 low background noise and high reproducibility was obtained with the N-terminal part of the
413 S1-protein. For the set-up, over 762 plasma samples, collected between 2017 and 2018, were
414 tested to define a tight cut off. In comparison to the Euroimmun S1 protein, the
415 Immundiagnostik protein is 156 amino acid shorter and the common region differs by four
416 amino acids.

417 Overall, neutralizing antibodies are considered one of the main parameters to measure
418 protective immunity against SARS-CoV-2, although their role in case of ongoing disease is
419 discussed more controversial [35-38]. Thus, the detection of neutralizing antibodies could
420 play a key role in monitoring vaccine efficacy but since biosafety requirements are high, it is
421 of outstanding interest that new serologic immunoassays are not only more sensitive, but also
422 correlate well with neutralization assays [39-41]. Recent studies indicated that commercial
423 assays targeting the S protein often correlate better with neutralizing antibody titers than those
424 targeting the NC protein [42, 43]. Likewise, our presented data suggest that in general
425 populations of individuals recovered from SARS-CoV-2 infection, immunoassays targeting
426 the S antigen correlated to a higher degree with results from the virus neutralizing assay than

427 those targeting the NC protein. In the special group of “non-responders”, the serologic test by
428 Immundiagnostik achieved the highest correlation with results from the virus neutralizing
429 assay, and the concordance was highest if low neutralizing titers of 1:10 were considered as
430 cutoff value for positivity. On the other hand, the Euroimmun assay achieved a better
431 concordance if a cutoff of 1:50 for neutralization was chosen in the unbiased group. These
432 results confirm the higher sensitivity of Immundiagnostik assay and the ability to detect low-
433 level neutralizing antibodies but it is unclear which serum antibodies titers can be considered
434 as protective. Although the proportion of IgG seropositive individuals appears to be higher if
435 tested with more sensitive immunoassays, which are at the same time highly specific, the
436 potential of these low antibody levels to serve as markers of beneficial immune functions
437 remains to be further investigated. Recent studies found that the memory B cell compartment
438 remains stable with the ability to generate potent neutralizing antibodies upon re-exposure to
439 SARS-CoV-2 and thus might represent a more suitable marker for humoral immune response
440 than antibody titers [23, 44].

441 **Conclusions**

442 Our study has two main outcomes. Firstly, we found the serological assays by Im-
443 mundiagnostik and Roche to be the most sensitive commercial tests from those evaluated.
444 Their combined use would be for example an advisable option in order to differentiate
445 infected from vaccinated. Secondly, we found that more than half of those participants who
446 recovered from SARS-CoV-2 infection but with undetectable IgG antibodies using the
447 commercial test by Euroimmun to be IgG seropositive when tested by Roche and
448 Immundiagnostik. Compared to Roche, the new serological assay by Immundiagnostik
449 correlated better with serum neutralizing activity, particularly in patients with only low
450 antibody concentrations after presumably mild infection. The protective role of detectable
451 low-level neutralizing activity deserves further investigation, considering the increasing data
452 pointing to the role of memory B cell compartment.

453

454 **Supplementary Materials:** Supplementary Table 1: Dataset; Supplementary Table 2:
455 Sensitivity of five commercially available serological tests, combination of tests, and one
456 virus-neutralizing immunoassay in a cohort with previous infection with SARS-CoV-2.;
457 Supplementary Table 3: Sensitivity of four commercially available serological tests,
458 combination of tests, and one virus-neutralizing immunoassay in a cohort with previous
459 infection with SARS-CoV-2 but undetectable IgG antibodies by the Euroimmun assay;
460 Supplementary Table 4: Specificity of five commercially available serological tests,

461 combination of tests, and one virus-neutralizing immunoassay in a SARS-CoV-2 negative
462 control group.

463 **Author Contributions:** Conceptualization, Kirsten Alexandra Eberhardt, Felix Dewald,
464 Kanika Vanshylla, Manuel Koch, Florian Klein and Veronica Di Cristanziano; Formal
465 analysis, Kirsten Alexandra Eberhardt, Felix Dewald and Veronica Di Cristanziano;
466 Investigation, Kirsten Alexandra Eberhardt, Felix Dewald, Eva Heger, Lutz Gieselmann,
467 Kanika Vanshylla, Maike Wirtz, Franziska Kleipass, Philipp Schommers, Henning Gruell,
468 Karl August Brensing, Roman-Ulrich Müller, Max Augustin, Clara Lehmann and Veronica
469 Di Cristanziano; Methodology, Felix Dewald, Manuel Koch and Veronica Di Cristanziano;
470 Project administration, Manuel Koch and Florian Klein; Resources, Wibke Johannis, Manuel
471 Koch and Florian Klein; Supervision, Florian Klein and Veronica Di Cristanziano; Writing –
472 original draft, Kirsten Alexandra Eberhardt, Felix Dewald and Veronica Di Cristanziano;
473 Writing – review & editing, Eva Heger, Lutz Gieselmann, Kanika Vanshylla, Maike Wirtz,
474 Franziska Kleipass, Wibke Johannis, Philipp Schommers, Henning Gruell, Karl August
475 Brensing, Roman-Ulrich Müller, Max Augustin, Clara Lehmann, Manuel Koch and Florian
476 Klein.

477

478 **Funding:** This work was funded by grants from the German Center for Infection
479 Research (DZIF to F.Klein), the German Research Foundation (DFG; CRC 1279, F.Klein;
480 CRC 1310, F.Klein; FOR2722, M.K.), the European Research Council (ERC-StG639961,
481 F.Klein), and COVIM: „NaFoUniMedCovid19“ (FKZ: 01KX2021).

482 Data Availability Statement: All observation data are accessible via the Supplementary
483 Materials.

484

485 **Acknowledgments:** We thank all participants contributing to this study. Furthermore, we owe
486 special thanks to Dr. Franz Paul Armbruster, Claudia Schumann, Sabine Friedl, Dagmar
487 Szellas, Guerino Rizzo, and Dr. Eva-Maria Rogg from Immundiagnostik for establishing the
488 ELISA kit in collaboration with the University Hospital Cologne. Figure 1 was created with
489 BioRender.com.

490

491 **Conflicts of Interest:** The University of Cologne (Medical Faculty) receives royalties for the
492 co-development of the IDK® anti-SARS-CoV-2 IgG ELISA and IDK® anti-SARS-CoV-2
493 IgM ELISA kits. IDK® had no role in the design of the study; in the collection, analyses, or
494 interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

495
496
497
498
499

References

- 500 1. Seow, J., et al., Longitudinal observation and decline of neutralizing antibody
501 responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol*,
502 2020. 5(12): p. 1598-1607.
- 503 2. Addetia, A., et al., Neutralizing Antibodies Correlate with Protection from SARS-
504 CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. *J Clin*
505 *Microbiol*, 2020. 58(11).
- 506 3. Wajnberg, A., et al., Robust neutralizing antibodies to SARS-CoV-2 infection persist
507 for months. *Science*, 2020. 370(6521): p. 1227-1230.
- 508 4. Weinstein, M.C., et al., Waiting for Certainty on Covid-19 Antibody Tests - At What
509 Cost? *N Engl J Med*, 2020. 383(6): p. e37.
- 510 5. Tang, M.S., et al., Association between SARS-CoV-2 neutralizing antibodies and
511 commercial serological assays. *Clin Chem*, 2020.
- 512 6. Salazar, E., et al., Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain
513 and re-ceptor-binding domain IgG correlate with virus neutralization. *J Clin Invest*, 2020.
514 130(12): p. 6728-6738.
- 515 7. FIND. SARS-COV-2 DIAGNOSTIC PIPELINESARS-COV-2 DIAGNOSTIC
516 PIPELINE-COV-2 DIAGNOSTIC PIPELINE-COV-2 DIAGNOSTIC PIPELINE. 2021 24
517 Feb 2021]; Available from: [http://www.finddx.org/covid-19/pipeline/?section=show-](http://www.finddx.org/covid-19/pipeline/?section=show-all#diag_tab)
518 [all#diag_tab](http://www.finddx.org/covid-19/pipeline/?section=show-all#diag_tab).
- 519 8. Coste, A.T., et al., Comparison of SARS-CoV-2 serological tests with different
520 antigen targets. *J Clin Virol*, 2020. 134: p. 104690.
- 521 9. Boonyaratanakornkit, J., et al., Clinical, laboratory, and temporal predictors of
522 neutralizing antibodies to SARS-CoV-2 among COVID-19 convalescent plasma donor
523 candidates. *J Clin Invest*, 2020.
- 524 10. Muecksch, F., et al., Longitudinal Serological Analysis and Neutralizing Antibody
525 Levels in Coronavirus Disease 2019 Convalescent Patients. *J Infect Dis*, 2021. 223(3): p. 389-
526 398.
- 527 11. Group, N.S.-C.-S.A.E., Performance characteristics of five immunoassays for SARS-
528 CoV-2: a head-to-head benchmark comparison. *Lancet Infect Dis*, 2020. 20(12): p. 1390-
529 1400.
- 530 12. Takeshita, M., et al., Incomplete humoral response including neutralizing antibodies in
531 asymptomatic to mild COVID-19 patients in Japan. *Virology*, 2021. 555: p. 35-43.
- 532 13. Petersen, L.R., et al., Lack of antibodies to SARS-CoV-2 in a large cohort of
533 previously infected persons. *Clin Infect Dis*, 2020.
- 534 14. Oved, K., et al., Multi-center nationwide comparison of seven serology assays reveals
535 a SARS-CoV-2 non-responding seronegative subpopulation. *EClinicalMedicine*, 2020. 29: p.
536 100651.
- 537 15. Gudbjartsson, D.F., et al., Humoral Immune Response to SARS-CoV-2 in Iceland. *N*
538 *Engl J Med*, 2020. 383(18): p. 1724-1734.
- 539 16. Vanshylla, K., et al., Kinetics and correlates of the neutralizing antibody response to
540 SARS-CoV-2. 2021.
- 541 17. Marklund, E., et al., Serum-IgG responses to SARS-CoV-2 after mild and severe
542 COVID-19 infection and analysis of IgG non-responders. *PLoS One*, 2020. 15(10): p.
543 e0241104.

- 544 18. Long, Q.X., et al., Clinical and immunological assessment of asymptomatic SARS-
545 CoV-2 infections. *Nat Med*, 2020. 26(8): p. 1200-1204.
- 546 19. Self, W.H., et al., Decline in SARS-CoV-2 Antibodies After Mild Infection Among
547 Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August
548 2020. *MMWR Morb Mortal Wkly Rep*, 2020. 69(47): p. 1762-1766.
- 549 20. Takahashi, S., B. Greenhouse, and I. Rodríguez-Barraquer, Are Seroprevalence
550 Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased? *J Infect Dis*, 2020.
551 222(11): p. 1772-1775.
- 552 21. Vogl, T., S. Leviatan, and E. Segal, SARS-CoV-2 antibody testing for estimating
553 COVID-19 prevalence in the population. *Cell Rep Med*, 2021. 2(2): p. 100191.
- 554 22. Henderson, J.P., What are protective antibody responses to pandemic SARS-CoV-2? *J*
555 *Clin Invest*, 2020. 130(12): p. 6232-6234.
- 556 23. Hartley, G.E., et al., Rapid generation of durable B cell memory to SARS-CoV-2
557 spike and nucleocapsid proteins in COVID-19 and convalescence. *Sci Immunol*, 2020. 5(54).
- 558 24. Cohen, J.I. and P.D. Burbelo, Reinfection with SARS-CoV-2: Implications for
559 Vaccines. *Clin Infect Dis*, 2020.
- 560 25. Crawford, K.H.D., et al., Protocol and Reagents for Pseudotyping Lentiviral Particles
561 with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses*, 2020. 12(5).
- 562 26. Coppeta, L., et al., Seroprevalence for vaccine-preventable diseases among Italian
563 healthcare workers. *Hum Vaccin Immunother*, 2020: p. 1-5.
- 564 27. Catry, E., et al., Analytical and clinical evaluation of four commercial SARS-CoV-2
565 sero-logical immunoassays in hospitalized patients and ambulatory individuals. *J Virol*
566 *Methods*, 2021. 289: p. 114060.
- 567 28. Eberhardt, K.A., et al., RNAemia Corresponds to Disease Severity and Antibody
568 Response in Hospitalized COVID-19 Patients. *Viruses*, 2020. 12(9).
- 569 29. Li, K., et al., Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2
570 infection and recovery from COVID-19. *Nat Commun*, 2020. 11(1): p. 6044.
- 571 30. Wolf, J., et al., Differences of SARS-CoV-2 serological test performance between
572 hospitalized and outpatient COVID-19 cases. *Clin Chim Acta*, 2020. 511: p. 352-359.
- 573 31. Milani, G.P., et al., Serological follow-up of SARS-CoV-2 asymptomatic subjects. *Sci*
574 *Rep*, 2020. 10(1): p. 20048.
- 575 32. Pflüger, L.S., et al., Clinical evaluation of five different automated SARS-CoV-2
576 serology assays in a cohort of hospitalized COVID-19 patients. *J Clin Virol*, 2020. 130: p.
577 104549.
- 578 33. Harley, K. and I.L. Gunsolus, Comparison of the Clinical Performances of the Abbott
579 Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays.
580 *J Clin Micro-biol*, 2020. 59(1).
- 581 34. Nasrallah, G.K., et al., Are commercial antibody assays substantially underestimating
582 SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure
583 setting. 2020.
- 584 35. Zohar, T. and G. Alter, Dissecting antibody-mediated protection against SARS-CoV-
585 2. *Nat Rev Immunol*, 2020. 20(7): p. 392-394.
- 586 36. Soresina, A., et al., Two X-linked agammaglobulinemia patients develop pneumonia
587 as COVID-19 manifestation but recover. *Pediatr Allergy Immunol*, 2020. 31(5): p. 565-569.
- 588 37. Legros, V., et al., A longitudinal study of SARS-CoV-2-infected patients reveals a
589 high correlation between neutralizing antibodies and COVID-19 severity. *Cell Mol Immunol*,
590 2021.
- 591 38. Lumley, S.F., et al., Antibody Status and Incidence of SARS-CoV-2 Infection in
592 Health Care Workers. *N Engl J Med*, 2020.
- 593 39. Mulligan, M.J., et al., Phase I/II study of COVID-19 RNA vaccine BNT162b1 in
594 adults. *Nature*, 2020. 586(7830): p. 589-593.

- 595 40. Luchsinger, L.L., et al., Serological Assays Estimate Highly Variable SARS-CoV-2
596 Neutral-izing Antibody Activity in Recovered COVID-19 Patients. *J Clin Microbiol*, 2020.
597 58(12).
- 598 41. Jääskeläinen, A.J., et al., Performance of six SARS-CoV-2 immunoassays in
599 comparison with microneutralisation. *J Clin Virol*, 2020. 129: p. 104512.
- 600 42. Valdivia, A., et al., Inference of SARS-CoV-2 spike-binding neutralizing antibody
601 titers in sera from hospitalized COVID-19 patients by using commercial enzyme and
602 chemiluminescent immunoassays. *Eur J Clin Microbiol Infect Dis*, 2021.
- 603 43. McAndrews, K.M., et al., Heterogeneous antibodies against SARS-CoV-2 spike
604 receptor binding domain and nucleocapsid with implications for COVID-19 immunity. *JCI*
605 *Insight*, 2020. 5(18).
- 606 44. Gaebler, C., et al., Evolution of antibody immunity to SARS-CoV-2. *Nature*, 2021.
607